Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Position Lifted by Braidwell LP

Braidwell LP raised its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 410.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,125,183 shares of the company’s stock after acquiring an additional 2,513,383 shares during the quarter. Apellis Pharmaceuticals makes up 2.6% of Braidwell LP’s portfolio, making the stock its 12th biggest position. Braidwell LP’s holdings in Apellis Pharmaceuticals were worth $90,130,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in APLS. Russell Investments Group Ltd. lifted its position in shares of Apellis Pharmaceuticals by 1,300.8% in the 1st quarter. Russell Investments Group Ltd. now owns 3,586 shares of the company’s stock worth $211,000 after buying an additional 3,330 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its position in shares of Apellis Pharmaceuticals by 107.7% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 16,677 shares of the company’s stock worth $981,000 after buying an additional 8,647 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Apellis Pharmaceuticals by 4.7% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 20,057 shares of the company’s stock worth $1,179,000 after buying an additional 903 shares during the last quarter. Tidal Investments LLC bought a new position in shares of Apellis Pharmaceuticals in the 1st quarter worth about $266,000. Finally, Comerica Bank lifted its position in shares of Apellis Pharmaceuticals by 500.7% in the 1st quarter. Comerica Bank now owns 8,163 shares of the company’s stock worth $480,000 after buying an additional 6,804 shares during the last quarter. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Stock Up 4.6 %

NASDAQ:APLS opened at $34.14 on Friday. Apellis Pharmaceuticals, Inc. has a one year low of $24.34 and a one year high of $73.80. The company has a fifty day moving average price of $28.69 and a 200 day moving average price of $35.40. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The business had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. Apellis Pharmaceuticals’s revenue was up 78.3% on a year-over-year basis. During the same period in the previous year, the business posted ($1.17) earnings per share. As a group, equities research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.72 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on APLS shares. Royal Bank of Canada restated a “sector perform” rating and issued a $25.00 price target on shares of Apellis Pharmaceuticals in a research report on Monday, November 4th. Bank of America dropped their price objective on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Mizuho dropped their price objective on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a report on Thursday, October 24th. William Blair assumed coverage on shares of Apellis Pharmaceuticals in a report on Wednesday, October 16th. They issued an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating on the stock in a report on Friday, September 13th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $49.94.

Insider Buying and Selling

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the sale, the director now owns 100,000 shares in the company, valued at $3,623,000. This trade represents a 27.01 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 6.80% of the stock is currently owned by corporate insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).